Advertisement
"InteKrin is very pleased to have Skyline, a premier health care venturefirm, lead its Series C financing," remarked InteKrin's President and CEODenny Lanfear. "This investment and the ongoing support of our existinginvestors including Sofinnova and OrbiMed will allow us to fully prepareINT131 for the initiation of the Phase 3 studies in 1H10 and maintain ourrapid development pace."
Advertisement
"The nonclinical safety multiples seen with INT131 together with thestrong efficacy seen in the Phase 2a study present a unique profile,"commented Skyline Ventures' David Lowe Ph.D. "The biology of INT131 and itsdemonstrated ability to selectively modulate PPAR gamma promises to deliver topatients glucose lowering efficacy without the safety compromises of currentlyavailable insulin sensitizers."
INT131 was designed specifically to antagonize characteristic TZD adverseeffects while retaining powerful PPAR gamma anti-diabetic efficacy, andrepresents a new product and chemical class. INT131 is well positioned tofulfill the unmet medical need for a safe treatment of insulin resistance, thekey etiological feature in the onset and subsequent progression of T2DM andmetabolic syndrome.
Phase 2a clinical efficacy data was presented in June 2008 at ADA and newnonclinical safety data will be presented next month at EASD. InteKrin'spreviously announced 360 patient, 24 week placebo controlled Phase 2b studywith a 45mg Actos(R) comparator arm was initiated in February, 2008 andresults are expected to be completed in 2H09.
About InteKrin (http://www.InteKrin.com):
InteKrin Therapeutics is a privately-held clinical-stage drug developmentcompany focused on diabetes, obesity and metabolic disease. InteKrin'sbusiness strategy is to build a robust portfolio of high value products by in-licensing clinical-stage therapeutic candidates that address significant unmetmedical needs and rapidly move them through critical development stages.InteKrin's team of world-class scientific and medical experts includesveterans from several successful BioPharma organizations, internationallyrecognized experts in nuclear receptors and metabolism, top scientistsformerly with the Food and Drug Administration and key clinical andcommercialization leaders.
To learn more about InteKrin, visit http://www.InteKrin.com.
SOURCE InteKrin Therapeutics, Inc.
